Literature DB >> 20615064

SELDI-TOF serum proteomics and colorectal cancer: a current overview.

Timo Gemoll1, Uwe Johannes Roblick, Gert Auer, Hans Jörnvall, Jens Karsten Habermann.   

Abstract

Surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a widely used technology platform for diagnostic biomarker discovery in tissue, plasma and serum. High-throughput and simplicity of experimental procedures have allowed this technology to become an important research tool for biomarker discovery during the last years. This review provides an overview of SELDI-TOF functionality, its advantages and drawbacks and gives a current literature overview of colorectal cancer based serum biomarker detection. Further improvements in instrumentation sensitivity and labelling chemistries will enable detection of novel, tissue-leakage biomarkers in serum. However, major emphasis should be given on subsequent identification of differentially observed protein peaks detected by SELDI-TOF. Clinical validation in large patient cohorts will then allow transferring novel biomarkers into clinical use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20615064     DOI: 10.3109/13813455.2010.495130

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  8 in total

1.  Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma.

Authors:  Chibo Liu; Chunqin Pan; Yong Liang
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

2.  Serum amyloid a protein in clinical cancer diagnosis.

Authors:  Chibo Liu
Journal:  Pathol Oncol Res       Date:  2011-09-08       Impact factor: 3.201

Review 3.  Proteomics for discovery of candidate colorectal cancer biomarkers.

Authors:  Paula Alvarez-Chaver; Olalla Otero-Estévez; María Páez de la Cadena; Francisco J Rodríguez-Berrocal; Vicenta S Martínez-Zorzano
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 4.  Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: where are we now in the era of the next generation proteomics?

Authors:  Jong-Min Park; Na Young Han; Young-Min Han; Mi Kyung Chung; Hoo Keun Lee; Kwang Hyun Ko; Eun-Hee Kim; Ki Baik Hahm
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS.

Authors:  Toon Van Gorp; Isabelle Cadron; Anneleen Daemen; Bart De Moor; Etienne Waelkens; Ignace Vergote
Journal:  Proteome Sci       Date:  2012-06-13       Impact factor: 2.480

6.  Effect of Xinjiang Uyghur Vernonia anthelmintica Willd Injection Treatment with Silicosis Fibrosis.

Authors:  Guitao Liu; Yingjia Liu; Lu Jin; Cuidong Li; Liping Nie; Yanhua Wei; Wenyu Wang; Yuhong Xu; Nuziguli Nusilaiti; Ping Hua; Xiujuan Li; Xiaohua Wang; Wenlong Wei; Hamulati Wufuer
Journal:  Biomed Res Int       Date:  2016-10-10       Impact factor: 3.411

7.  Determination of Serum Lost Goodwill Target Proteome in Patients with Severe Traumatic Brain Injury.

Authors:  Hongming Ji; Changchen Hu; Gangli Zhang; Jinrui Ren; Yihu Tan; Wenxiao Sun; Junwen Wang; Jun Li; Hongchao Liu; Ruifan Xie; Zhipeng Hao; Dongsheng Guo
Journal:  Biomed Res Int       Date:  2015-09-27       Impact factor: 3.411

8.  The Human Urinary Proteome Fingerprint Database UPdb.

Authors:  Holger Husi; Janice B Barr; Richard J E Skipworth; Nathan A Stephens; Carolyn A Greig; Henning Wackerhage; Rona Barron; Kenneth C H Fearon; James A Ross
Journal:  Int J Proteomics       Date:  2013-10-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.